[Predictive factors of clinically significant drug-drug interactions among regimens based on protease inhibitors, non-nucleoside reverse transcriptase inhibitors and raltegravir].

M. Cervero,R. Torres,J. Jusdado,S. Pastor,J. L. Agud
DOI: https://doi.org/10.1016/j.medcli.2016.01.016
2016-04-15
Abstract:
What problem does this paper attempt to address?